Efficacy of indapamide 1.5mg, sustained release, in the lowering of systolic blood pressure

Journal of Human Hypertension

Volumn 18, Issue SUPPL. 2, 2004, Pages

  London, G M ^a  

^a Hopital Manhes   (France)

Author keywords

Cardiovascular risk; Indapamide 1.5mg sustained release; Systolic blood pressure

Indexed keywords

AMLODIPINE; ATENOLOL; ENALAPRIL; HYDROCHLOROTHIAZIDE; INDAPAMIDE; THIAZIDE DIURETIC AGENT;

ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BACKACHE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMORBIDITY; DOSE RESPONSE; DRUG EFFICACY; ELDERLY CARE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; LOW DRUG DOSE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; PERIPHERAL EDEMA; RISK ASSESSMENT; SUSTAINED RELEASE FORMULATION; SYSTOLIC BLOOD PRESSURE; SYSTOLIC HYPERTENSION; TARGET ORGAN;

AGED; ALBUMINURIA; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DELAYED-ACTION PREPARATIONS; DIABETES MELLITUS, TYPE 2; DIURETICS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; INDAPAMIDE; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 12744280985     PISSN: 09509240     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.jhh.1001799     Document Type: Article

References (35)

1. Kannel WB. Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA 1996; 24: 1571-1576.
2. Kannel WB, Stokes JLL. Hypertension as a cardiovascular risk factor. In: Bulpitt CJ (ed). Hand Book of Hypertension. Epidemiology of Hypertension. Elsevier Science: Amsterdam, 1985, pp 15-34.
3. Sagie A, Larson MG, Levy D. The natural history of borderline isolated systolic hypertension. N Engl J Med 1993; 329: 1912-1917.
4. Black HR. The paradigm has shifted to systolic blood pressure. Hypertension 1999; 34: 386-387.
5. Lewington S et al. Age-related relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360 1903-1913.
6. Black HR et al. Baseline characteristics of the 16 605 patients in the CONVINCE study [Abstract]. J Hypertens 1999; 17 S201.
7. Cushman WC et al. Blood pressure control in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial [Abstract]. Am J Hypertens 1998; 11: 17A.
8. Safar ME, London GM. The arterial system in human hypertension. In: Swales JD (ed). Textbook of Hypertension. Blackwell Scientific: London, 1994, pp 85-102.
9. Nichols WW, O'Rourke M. McDonald's Blood Flow in Arteries. Theoretical, Experimental and Clinical Principles, 4th edn. E. Arnold: London, Sydney, Auckland, 1998, pp 54-113, 201-222, 284-292, 347-401.
10. Franklin SS et al. Haemodynamic patterns of age-related changes in blood pressure. The Framingham Heart Study. Circulation 1997; 96: 308-315.
11. Systolic Hypertension in the Elderly Program Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265: 3255-3264.
12. Somes GW et al. The role of diastolic blood pressure when treating isolated systolic hypertension. Arch Intern Med 1999; 159: 2004-2009.
13. Franklin SS et al. Is pulse pressure useful in predicting risk for coronary heart disease? The Framingham Heart Study. Circulation 1999; 100: 354-360.
14. Millar JA, Lever AF, Burke V. Pulse pressure as a risk factor for cardiovascular events in the MRC mild hypertension trial. J Hypertens 1999; 17: 1065-1072.
15. Blacher J et al. Pulse pressure - not mean pressure - determines cardiovascular risks in older hypertensive patients. Arch Med 2000; 160: 1085-1089.
16. Domanski MJ et al. Isolated systolic hypertension, prognostic information provided by pulse pressure. Hypertension 1999; 34: 375-380.
17. Chobanian AV et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206-1252.
18. 2003 European Society of Hypertension. European Society of cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-1053.
19. Morgan T, Lauri J, Bertram D, Anderson A. Effect of different antihypertensive drug classes on central aortic pressure. Am J Hypertens 2004; 17: 118-123.
20. Donnelly R. Clinical implications of indapamide sustained release 1.5 mg in hypertension. Clin Pharmacokinet 1999; 37 Suppl 1): 21-32.
21. Ambrosioni E et al. Low-dose antihypertensive therapy with 1.5mg sustained-release indapamide: results of randomised double-blind controlled studies. European study group. J Hypertens 1998; 16: 1677-1684.
22. Emeriau JP, et al., European Study Investigators. A comparison of indapamide SR 1.5mg with both amlodipine 5mg and hydrochlorothiazide 25mg in elderly hypertensive patients: a randomized double-blind controlled study. J Hypertens 2001; 19: 343-350.
23. Leonetti G et al. Evaluation of long-term efficacy of indapamide SR 1.5mg in elderly hypertensive patients. Am J Hypertens 2001; 14(Part 2): P221.
24. Marre M et al. Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes. The NESTOR study. J Hypertens 2004; 22: 1613-1622.
25. Marre M et al. The extent of microalbuminuria reduction with indapamide SR in elderly hypertensive type 2 diabetic patients. The NESTOR study. J Hypertens 2003; 21(Suppl 4): S183.
26. Gosse P et al. Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5mg vs enalapril 20mg: the LIVE study. J Hypertens 2000; 18: 1465-1475.
27. Gosse P et al. Centralized echocardiogram quality control in a multicenter study of regression of left ventricular hypertrophy in hypertension. J Hypertens 1998; 16: 531-535.
28. Du Cailhar G et al. Dietary sodium and pulse pressure in normotensive and essential hypertensive subjects. J Hypertens 2004; 22: 697-703.
29. Avolio AO et al. Effects of aging on changing arterial compliance and left ventricular load in a northern Chinese urban community. Circulation 1983; 68: 50-58.
30. Et-Taouil, Schiavi P, Levi BI, Plante GE. Sodium intake, large artery stiffness, and proteoglycans in the spontaneously hypertensive rat. Hypertension 2001; 38: 1172-1176.
31. Benetos A et al. Arterial stiffness, hydrochlorothiazide and converting enzyme inhibition in essential hypertension. J Human Hypertens 1996; 10: 77-82.
32. London G, Schmieder R, Calve C. Applanation tonometry: arterial mechanical properties of indapamide SR vs candesartan and amlodipine: the X-CELLENT tonometry study. J Hypertens 2004; 22 Suppl 2): S116.
33. Contri MB et al. Dose-dependent prevention of fibrosis in aorta of salt-loaded stroke-prone spontaneously hypertensive rats by combined delapril and indapamide treatment. J Cardiovasc Pharmacol 2002; 40: 388-398.
34. Ambrosioni E, Veronesi M. Clinical role of Natrilix SR in the treatment of at-risk hypertensive patients. J Hypertens 2003; 21 Suppl 1): S13-S17.
35. Weidmann P. Metabolic profile of indapamide sustained release in patients with hypertension. Data from three double blind studies. Drug Safety 2001; 24: 1155-1165.